The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70 - Concepedia

Concepedia

Publication | Open Access

The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70

DOI Full Paper Access

90

Citations

12

References

2021

Year

Céline Boutry, Andrew Hastie, Javier Díez‐Domingo, Juan Carlos Tinoco, Chong‐Jen Yu, Charles P. Andrews, Jean Beytout, Covadonga Caso, Huey‐Shinn Cheng, Hee Jin Cheong,

Clinical Infectious Diseases

Abstract

Efficacy against HZ and immune responses to RZV remained high, suggesting that the clinical benefit of RZV in older adults is sustained for at least 7 years post-vaccination. Clinical Trials Registration. NCT02723773.

References

	Year	Citations

Page 1